CRISPR Therapeutics AG (CRSP) Actualités

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a...

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and...